Long-term follow-up of R403W MYH7 and R92W TNNT2 HCM families : mutations determine left ventricular dimensions but not wall thickness during disease progression by Revera, Miriam et al.
146 CARDIOVASCULAR JOURNAL OF AFRICA Vol 18, No. 3, May/June 2007
Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM 
families: mutations determine left ventricular  
dimensions but not wall thickness during disease 
progression 
MIRIAM REVERA, LIZE VAN DER MERWE, MARSHALL HERADIEN, ALTHEA GOOSEN, VALERIE A CORFIELD,  
PAUL A BRINK, JOHANNA C MOOLMAN-SMOOK
Summary
Background: The clinical profile and prognosis of patients 
with hypertrophic cardiomyopathy, a primary cardiac 
muscle disease caused mostly by mutations in sarcomeric 
protein-encoding genes, have been linked to particular 
disease-causing mutations in the past. However, such asso-
ciations are often based on cross-sectional observations, 
as longitudinal studies of the progression of the disease in 
genotypically defined patients are sparse. Most importantly, 
the relative contribution of age, gender and genetic cause to 
disease profile and progression has not yet been reported, 
and the question remains whether one or more of these 
factors could mask the effect of the other(s).
Methods: We previously described cross-sectional family 
studies of two hypertrophic cardiomyopathy (HCM)-caus-
ing mutations, R92WTNNT2 and R403WMYH7, both associated 
with minimal hypertrophy, but with widely different life 
expectancies. We re-investigated 22 and 26 R92WTNNT2 and 
R403WMYH7 mutation carriers in these and additional South 
African R92WTNNT2 families after a mean 11.08 ± 2.79 years, 
and compared the influence of the two mutations, in the 
context of age and gender, on disease progression.
Results: We demonstrated a positive correlation between age 
and interventricular septal thickness for both mutations, 
with more than a third of all mutation carriers develop-
ing clinically recognised hypertrophy only after the age of 
35 years. This period of hypertrophically silent HCM also 
coincided with the years in which most sudden cardiac 
deaths occurred, particularly in male R92WTNNT2 carriers. 
Statistical analyses indicated that the particular mutation 
was the strongest determinant of left ventricular remodel-
ling; particularly, LvESD increased and Ef reduction was 
noted in the majority of R403WMYH7 carriers, which may 
require clinical follow-up over the longer term.
Conclusions: Statistical modelling of follow-up data suggests 
that an interplay between unidentified, possibly gender-
associated factors, and the causal mutation are the deter-
minants of eventual cardiac function and survival, but not 
of the extent of hypertrophy, and emphasises the need for 
long-term follow-up even in individuals with apparently 
mild disease.
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Hypertrophic cardiomyopathy (HCM), a common cardiac 
muscle disorder, is mainly caused by mutations in genes encod-
ing sarcomeric proteins, with resultant changes in the morphol-
ogy of the ventricular muscle.1 While hypertrophy is reported 
to typically develop rapidly between puberty and early adult-
hood,2,3 with subsequent wall thinning and systolic dysfunction 
associated with aging,4 HCM caused by mutations in the cardiac 
myosin-binding protein C gene (MYBPC3) has been associated 
with progressive hypertrophy.5 The disease carries an increased 
risk for sudden cardiac death (SCD) but progresses to a dilated 
cardiomyopathy-like phenotype in 10 to 15% of cases, some of 
whom die from heart failure.6,7 Remodelling impacts on patient 
management, and differentiating factors which predispose 
towards progressive hypertrophy, SCD or heart failure (HF) 
have prognostic implications.
The clinical phenotype of HCM, including risk for SCD 
and/or cardiac dilation, has previously been linked to particular 
disease-causing mutations.8,9 However, such conclusions are 
often based on cross-sectional observations, as longitudinal 
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studies of the progression of the disease in genotypically defined 
patients are sparse. Most importantly, the relative contribution 
of age, gender and genetic cause to disease progression has not 
yet been reported, and the question remains whether one or more 
of these factors could mask the effect of the other(s).
We previously described cross-sectional family studies of 
two HCM-causing mutations, R92WTNNT2 and R403WMYH7,
10,11 
which were both associated with minimal hypertrophy, but with 
widely different life expectancy, namely a high incidence of 
early sudden death in R92WTNNT2 carriers, but normal life expect-
ancy in R403WMYH7 carriers.
10-13 We re-investigated mutation 
carriers in these and three additional South African R92WTNNT2 
families after an extended period, and compared the influence of 
the two mutations, in the context of age and gender, on disease 
progression in adults.
Methods
Informed consent was obtained from study participants and 
the institutional review board of the University of Stellenbosch 
(N04/03/062). Pedigree 106, in whom the R403WMYH7 muta-
tion segregates,11 and pedigrees 100 and 109,10 in whom the 
R92WTNNT2 mutation segregates, have been described previously. 
During routine mutation screening of HCM-causing genes in 
a panel of consecutively referred, apparently unrelated HCM 
patients,14 three additional index cases with the R92WTNNT2 
mutation were identified. Pedigrees derived from these indi-
viduals were designated 103, 137 and 139 and immediate family 
members of these index cases were tested for the R92WTNNT2 
mutation. Mutation testing was performed on genomic DNA 
derived from peripheral blood nucleated cells, in duplicate but 
independent analyses, by PCR-based allele-specific restriction 
enzyme digestion, as described previously.10,11
Follow-up clinical evaluation was essentially performed as 
described previously10,11 and entailed cross-sectional echocardi-
ography on a General Electric Vivid-7 cardiovascular imaging 
system, with standard left ventricular measurements taken with 
M-mode echocardiography. Symptoms (syncope or presyncope, 
tachycardia, dyspnoea, chest pain) known to occur in HCM, 
blood pressure and athletic activity were also recorded for these 
individuals.
Total family history, not only events occurring during 
the follow-up period, was used to obtain the total number of 
disease-related deaths, circumstances of death, and age at death. 
Sudden cardiac deaths as well as heart failure-related deaths 
(HF), when occurring in mutation carriers or individuals with a 
diagnosis of HCM or with a history of syncope, were considered 
HCM-related deaths.
Statistical analysis
Differences in parameter medians between carriers of the 
R92WTNNT2 and the R403WMYH7 mutations were compared for 
statistical significance using the Kruskal-Wallis test. Spearman’s 
method was used to assess the correlation of age, gender and 
mutation with parameters of progression, ie, the measurements 
of end-diastolic interventricular septal thickness (IVS) and 
posterior wall thickness (PW), left ventricular end-diastolic 
(LVEDD) and end-systolic diameter (LVESD), left ventricular 
ejection fraction (EF) and left atrial diameter (LAD) at final 
evaluation, as well as the degree of change in these parameter. 
The latter was defined as:
(last measurement – first measurement) 
3 100              first measurement
Additionally, we used a backwards stepwise procedure to 
identify the set of factors contributing to an optimal multiple 
linear regression model for the principal left ventricular (LV) 
dimension parameters, LVEDD and LVESD at final evalua-
tion. This stepwise procedure was initiated from multiple linear 
regression models expressing the principal parameter (depend-
ent variable) as a function of selected candidate predictive 
factors. These candidate factors were age, gender, mutation, 
follow-up time, final value of IVS and PW, and initial value of 
the particular parameter. Additionally, LVEDD at final evalu-
ation was included as a candidate contributor in the opening 
Fig. 1. Pedigrees of three newly identified families carry-
ing the R92WTNNT2 mutation.  Genotypic and phenotypic 
status is indicated in the key, squares indicate males and 
circles females. 
Fig. 2. Kaplan-Meier product-limit curves indicating 
deaths due to SCD or HF in gender-stratified individuals 
with either R92WTNNT2 or R403WMYH7 mutations. Survival 
was significantly different in males and females with the 
R92WTNNT2 mutation (p 5 0.005), with male R92WTNNT2 carri-
ers showing particularly poor survival before 35 years.
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model for prediction of final LVESD. In this process, factors are 
discarded one at a time, until the model with the lowest possible 
Akaike information criterion (AIC) is reached, indicating that 
the best combination of predictors that explains the variation in 
the dependent variables has been identified.
Survival functions were estimated by the Kaplan-Meier 
product limit method, and comparisons between groups tested 
by log-rank analysis. All SCD or HF deaths that had occurred 
within the families, not only those that occurred during the 
follow-up period, were considered for this analysis.
Results
While all R403WMYH7 carriers remained alive, five of the original 
31 R403WMYH7 carriers in pedigree 106 declined to participate 
in the follow-up study. Of the original 14 and five R92WTNNT2 
carriers in pedigrees 100 and 109, respectively, one individual in 
each pedigree declined participation and one (pedigree 109) had 
died in a motor vehicle accident. Moreover, during the follow-
up period, one female HCM-related death had occurred in each 
of pedigrees 100 (SCD: 62 years) and 109 (HF: 66 years). For 
the newly identified R92WTNNT2 pedigrees (Fig. 1), baseline 
and follow-up clinical data were available for one mutation 
carrier from pedigree 103, two from pedigree 137 and six from 
pedigree 139. In pedigrees 137 and 139, three and one males, 
respectively, had died of cardiac causes (pedigree 137: SCD: 15 
and 17 years; HF: 52 years; pedigree 139: SCD: 19 years, Fig. 
1). When comparing previously reported SCD- and HF-related 
deaths, which were all male,10 as well as those deaths which 
occurred during the follow-up period between gender-stratified 
mutation groups, R92WTNNT2 carriers, and particularly males, 
suffered more SCD- or HF-related deaths than any other group 
(male vs female R92WTNNT2: p 5 0.005, male R92WTNNT2 vs other 
groups: p 5 0.0005; Fig. 2). 
In total, 26 R403WMYH7 and 22 R92WTNNT2 carriers were clini-
cally re-evaluated after an average of 11.08 ± 2.79 years; indi-
vidual data are shown in Table 1. There was a preponderance of 
males in the R403WMYH7 group (65%), while the reverse was true 
in the R92WTNNT2 group (64% female). There was no statistically 
significant difference between the mean ages of either mutation 
group, or gender within or between groups at either the initial 
or final clinical evaluation. 
None of the individuals were athletically active during 
the follow-up period. Blood pressure remained essentially 
unchanged in all but one (female) individual in the R92WTNNT2 
group, who became hypertensive during the follow-up period; 
one male R92WTNNT2 and three R403WMYH7 individuals (one 
male) were hypertensive throughout the follow-up period. 
R92WTNNT2 carriers were more often symptomatic (46%), usually 
with syncope or palpitations, than R403WMYH7 carriers (15%). 
R403WMYH7 carriers more often demonstrated mitral regurgita-
tion (mild, 35 vs 27%). Three R403WMYH7 and two R92WTNNT2 
carriers were classified as NYHA class 2 by final assessment; 
only one individual (R92WTNNT2 carrier) had progressed further 
to class 3. Three R92WTNNT2 carriers demonstrated atrial fibrilla-
tion (AF) by final assessment; AF was absent in all R403WMYH7 
carriers. These additional features are shown in Table 2.
Changes in cardiac parameters during follow-up
Mean values for salient follow-up parameters at both time points 
are given in Table 3. Wall thickness was initially similarly mild 
Fig. 3. The relationship between wall thickness and age in R92WTNNT2 and R403WMYH7 carriers. (a) End-diastolic interven-
tricular septal thickness (IVS), and (b) posterior wall thickness increased with age in the majority of male and female 
carriers of R92WTNNT2 and R403WMYH7 mutations.
a)
b)
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TABLE 1. BASELiNE AND fiNAL vALuES of ECHoCARDioGRAPHiC PARAMETERS iN R92WTNNT2 AND R403MYH7  
MuTATioN CARRiERS
Ped Person
Mutation/
gene Gender
Age 1
(yrs)
Age 2
(yrs)
IVS 1
(mm)
IVS 2
(mm)
PW 1
(mm)
PW 2
(mm)
LAD 1
(mm)
LAD 2
(mm)
LVEDD 1
(mm)
LVEDD 2
(mm)
LVESD 1
(mm)
LVESD 2
(mm)
EF 1
(%)
EF 2
(%)
100 0_III_8 R92WTNNT2 M 35.0 48.0 7.0 14.3 7.0 8.6 28.0 38.0 51.0 40.9 30.0 22.6 66.5 70.8
100 0_III_17 R92WTNNT2 M 24.0 38.0 11.5 20.0 5.3 7.8 33.0 32.7 45.0 39.0 29.0 16.1 59.6 84.3
100 0_II_18 R92WTNNT2 F 43.0 57.0 7.0 20.3 7.0 9.5 34.0 47.7 51.0 45.4 34.0 24.4 56.5 72.0
100 0_III_20 R92WTNNT2 F 23.0 37.0 6.0 15.0 6.0 10.8 31.0 35.2 50.0 40.0 27.0 22.7 72.0 69.1
100 0_II_23 R92WTNNT2 F 37.0 51.0 12.0 19.3 13.0 13.2 45.0 48.2 44.0 38.6 27.0 25.8 63.5 56.8
100 0_II_10 R92WTNNT2 F 53.0 67.0 12.0 21.0 11.0 10.6 37.0 40.6 41.0 46.0 25.0 25.1 64.1 71.4
100 0_III_9 R92WTNNT2 F 24.0 38.0 8.0 16.0 8.0 9.0 39.0 46.0 45.0 47.2 31.0 33.2 53.6 51.5
100 0_III_12 R92WTNNT2 F 31.0 45.0 8.0 18.3 8.0 9.1 27.0 40.9 45.0 42.2 26.0 19.4 67.8 80.1
100 0_III_15 R92WTNNT2 F 28.0 42.0 13.8 13.8 7.5 7.2 34.0 36.2 42.0 41.2 26.0 19.4 62.9 79.1
100 0_III_5 R92WTNNT2 F 19.0 33.0 6.4 8.8 6.4 6.7 NA 26.3 52.0 46.7 30.0 27.2 67.8 67.2
100 0_III_22 R92WTNNT2 M 9.0 19.0 4.0 11.0 4.0 6.6 20.0 29.0 44.0 40.0 23.0 24.4 74.0 64.1
109 9_III_1 R92WTNNT2 F 30.0 41.0 20.0 17.4 11.0 10.7 30.0 34.0 37.0 41.0 17.0 25.0 80.3 64.1
109 9_IV_2 R92WTNNT2 F 11.0 21.0 5.0 7.1 5.0 6.0 24.0 31.0 47.0 43.0 30.0 29.0 60.0 55.7
103 3_II_2 R92WTNNT2 M 35.0 43.0 14.0 22.0 12.0 13.0 38.0 31.0 41.0 34.0 25.0 20.8 64.1 64.1
137 37_II_3 R92WTNNT2 M 46.0 57.0 7.0 16.0 9.0 10.0 38.0 48.8 50.0 48.0 30.0 28.0 65.1 67.1
137 37_III_2 R92WTNNT2 F 21.0 28.0 8.0 7.0 7.0 6.6 27.0 26.0 41.0 38.0 22.0 21.0 72.5 70.9
139 39_II_6 R92WTNNT2 M 35.0 40.0 14.0 16.8 6.4 10.0 36.0 36.0 43.0 40.0 26.0 24.7 64.7 63.2
139 39_II_4 R92WTNNT2 F 36.0 44.0 20.0 16.0 7.0 10.0 35.0 39.0 37.0 38.0 17.0 20.0 80.3 73.7
139 39_II_8 R92WTNNT2 F 30.0 36.0 5.2 6.0 5.5 6.3 28.0 22.0 39.0 35.0 22.0 20.0 69.5 68.9
139 39_III_2 R92WTNNT2 M 12.0 16.0 7.0 11.0 8.0 6.6 29.0 29.0 40.0 40.0 24.0 24.4 65.3 64.1
139 39_III_4 R92WTNNT2 M 14.0 20.0 8.1 7.6 7.4 8.0 NA 33.0 39.0 40.0 20.0 26.5 75.1 57.3
139 39_III_3 R92WTNNT2 F 11.0 17.0 6.8 8.4 6.2 7.8 NA 27.0 34.0 34.6 16.0 19.5 79.4 69.8
106 6_III_13 R403WMYH7 M 60.0 72.0 7.0 16.0 7.0 10.0 NA 33.5 57.0 42.5 33.0 25.4 67.4 65.5
106 6_III_15 R403WMYH7 M 53.0 65.0 9.0 13.8 8.0 8.7 31.0 37.0 51.0 45.0 27.0 NA 73.0 NA
106 6_III_22 R403WMYH7 F 46.0 58.0 11.0 22.7 10.0 9.0 34.0 42.0 40.0 39.0 22.0 24.2 71.1 62.8
106 6_III_7 R403WMYH7 F 49.0 61.0 10.0 12.2 9.0 12.0 22.0 25.5 46.0 40.0 27.0 25.2 66.7 61.6
106 6_IV_10 R403WMYH7 M 32.0 44.0 11.0 11.2 10.0 9.7 36.0 44.8 53.0 50.0 31.0 31.5 66.8 61.4
106 6_IV_11 R403WMYH7 M 29.0 41.0 11.0 13.0 9.0 8.0 33.0 42.0 51.0 44.5 32.0 26.0 61.7 67.1
106 6_IV_12 R403WMYH7 F 27.0 39.0 9.0 13.9 8.0 10.5 27.0 38.6 47.0 47.7 25.0 28.7 72.9 64.9
106 6_IV_22 R403WMYH7 M 36.0 50.0 18.0 19.0 13.0 8.3 43.0 50.0 48.0 47.0 28.0 27.0 67.1 68.2
106 6_IV_23 R403WMYH7 F 35.0 48.0 14.0 12.0 7.0 8.8 29.0 33.0 40.0 40.0 21.0 22.0 73.8 71.1
106 6_IV_24 R403WMYH7 F 35.0 47.0 9.3 13.0 8.0 11.8 33.0 50.0 48.0 52.5 21.0 36.0 82.0 53.9
106 6_IV_25 R403WMYH7 F 31.0 44.0 17.0 23.0 10.0 12.0 30.0 48.0 34.0 38.0 16.0 22.0 79.4 67.9
106 6_IV_31 R403WMYH7 M 25.0 36.0 5.0 15.4 5.0 8.1 36.0 35.2 56.0 48.0 34.0 29.0 64.1 64.6
106 6_IV_33 R403WMYH7 M 18.0 29.0 6.0 8.6 6.0 6.8 34.0 29.6 44.0 41.7 26.0 26.8 66.3 59.9
106 6_IV_6 R403WMYH7 M 38.0 50.0 8.0 13.7 7.0 9.8 35.0 41.7 54.0 51.0 33.0 33.7 63.6 57.3
106 6_IV_7 R403WMYH7 F 36.0 48.0 7.0 14.0 9.0 10.0 NA 41.4 49.0 46.7 24.0 29.0 77.1 62.6
106 6_IV_8 R403WMYH7 M 35.0 46.0 7.0 10.1 7.0 8.0 30.0 38.0 51.0 47.0 30.0 28.8 66.5 63.6
106 6_V_5 R403WMYH7 M 18.0 29.0 9.0 11.7 9.0 10.9 27.0 33.5 53.0 46.5 28.0 27.8 73.1 65.4
106 6_V_6 R403WMYH7 M 15.0 26.0 5.0 9.6 6.0 7.4 27.0 37.0 46.0 47.0 21.0 27.5 80.3 66.9
106 6_V_7 R403WMYH7 M 13.0 24.0 5.0 9.2 5.0 7.7 25.0 31.8 51.0 49.0 27.0 30.8 73.1 61.6
106 6_V_8 R403WMYH7 M 11.0 22.0 8.0 13.6 7.0 10.1 23.0 39.0 35.0 47.0 21.0 28.0 65.5 65.6
106 6_IV_2 R403WMYH7 F 8.0 19.0 7.0 13.3 6.0 7.4 29.0 26.0 43.0 38.4 24.0 23.8 70.1 63.0
106 6_IV_30 R403WMYH7 M 13.0 27.0 6.0 11.3 6.0 6.0 29.0 32.0 43.0 46.0 26.0 28.4 64.7 63.0
106 6_V_11 R403WMYH7 F 8.0 19.0 4.0 7.4 3.0 7.6 20.0 27.0 42.0 44.0 25.0 29.4 65.8 56.5
106 6_V_14 R403WMYH7 M 8.0 20.0 6.4 9.8 6.5 9.3 22.0 27.0 39.0 49.0 25.0 33.0 60.2 55.7
106 6_V_17 R403WMYH7 M 8.0 22.0 6.5 7.2 6.5 7.1 27.0 33.0 37.0 42.0 21.0 28.0 69.2 56.7
106 6_V_4 R403WMYH7 M 7.0 18.0 5.0 11.4 4.0 8.8 28.0 29.8 37.0 41.7 19.0 26.6 75.1 60.5
Person 5 numbers refer to pedigree identification numbers; see Fig. 1 for pedigrees 103, 137 and 139, references 10 for pedigree 100 and 109, 
and reference 11 for pedigree 106. 
Ped 5 pedigree, M 5 male, F 5 female, 1 5 baseline measurement, 2 5 final measurement, yrs 5 years, IVS 5 end-diastolic interventricular 
septal thickness, PW 5 end-diastolic posterior wall thickness, LAD 5 left atrial diameter, LVEDD 5 left ventricular end-diastolic diameter, 
LVESD 5 left ventricular end-systolic diameter, EF 5 ejection fraction, NA 5 not available.
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in both groups. With age, hypertrophy increased in the major-
ity of individuals as measured by increase in interventricular 
septum thickness (IVS) (Fig. 3a) and posterior wall (PW) (Fig. 
3b). This increase was marked (≥ 5 mm) in 50% of R92WTNNT2 
and in 39% of R403WMYH7 carriers, yet hypertrophy never 
became severe (> 30 mm) (Table 1). No marked wall thinning 
(≥ 5 mm) was noted for carriers of either mutation (Table 1); 
four R92WTNNT2 and five R403WMYH7 carriers showed a decrease 
in IVS or PW of < 5 mm over time. 
Ten of 22 R92WTNNT2 and 11 of 26 R403WMYH7 carriers devel-
oped clinically recognised hypertrophy (IVS ≥ 13 mm) during 
the follow-up period. For five of these 10 R92WTNNT2 carriers and 
four of these 11 R403WMYH7 carriers, this transition to clinical 
HCM occurred after 35 years, as their age at initial evaluation 
was ≥ 35 years (Table 1, Fig. 3a). 
The two groups of mutation carriers did not differ signifi-
cantly in follow-up parameters except for final LV dimensions, 
and consequently, for EF (Table 3). Indeed, LV remodel-
ling appeared to be more detrimental to cardiac function in 
R403WMYH7 rather than in R92WTNNT2 carriers, where it accom-
panied a decrease in EF in the majority of R403WMYH7 carriers 
(Table 1, 3), although final EF was still within the normal range. 
Although initially similar in both groups (Table 3), LV dimen-
sions decreased in the majority of R92WTNNT2 carriers (Table 
1, Fig. 4a, b). In contrast, although mean LVEDD decreased 
slightly (Table 3), LVESD increased in most R403WMYH7 carri-
ers (Table 1) and more strikingly in female R403WMYH7 carriers. 
Two-thirds of all female R403WMYH7 carriers showed an increase 
of ≥ 10% in LVESD, while comparable increases in LVESD 
in male R403WMYH7 carriers were restricted to individuals who 
were < 18 years at first evaluation (Table 1, Fig. 4b). 
The effect of age, gender and mutation on changes 
in cardiac parameters
Age, gender and mutation have been reported to influence cardi-
ac remodelling,4,8,9,15 therefore, to further investigate the predic-
tors of wall and chamber remodelling, correlations between 
these factors and final wall and chamber dimensions as well as 
the degree of change in these dimensions were investigated in 
the whole study sample. Whereas final IVS, PW and LAD and 
the degree of change in PW correlated significantly with age 
for carriers of either mutation, final LVEDD, LVESD and EF as 
well as the degree of change in these parameters correlated most 
strongly with mutation (Table 4). However, weak correlations of 
final EF and the degree of change in LVESD and EF with age, 
and of final LVEDD with gender were also noted (Table 4).
Therefore, to further investigate the quantitative relationship 
of these factors (mutation, age and gender) and LV dimen-
sions, multiple regression modelling was used. A best-fit final 
model which included age, mutation, follow-up time and initial 
LVEDD, LVEDD 2 ~ −0.057 3 age 1 0.36 3 follow-up time 
1 0.39 3 LVEDD 1 1 2.78 3 R403W, described 45.5% of the 
variability in final LVEDD (p 5 4.13e − 5). Similarly, a best-fit 
final model, which included final IVS and PW, mutation, as well 
as initial LVESD, LVESD 2 ~ −0.45 3 IVS 2 1 0.86 3 PW 2 
1 0.31 3 LVESD 1 1 0.3.50 3 R403W, described 43% of the 
variability in final LVESD (p 5 1.21e − 5). 
When individuals younger than 18 years of age at first 
evaluation were excluded in the regression modelling, in order 
to circumvent possible confounding effects of puberty-related 
changes in cardiac morphology on the apparent remodelling,2,3 
female gender was unmasked as a factor determining final 
LVEDD. In this model, 52% of the variation in final LVEDD 
Fig. 4. Left ventricular dimensions at baseline and final evaluation in male and female carriers of R92WTNNT2 and 
R403WMYH7 mutations. Although initially similar in both groups, (a) LV end-diastolic (LVEDD), as well as (b) systolic 
diameter (LVESD), decreased in the majority of R92WTNNT2 carriers, while LVESD increased in most R403WMYH7 carriers. 
1 5 baseline, 2 5 final evaluation; f 5 female, m 5 male.
a)
b)
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measurement could be explained by gender, mutation and initial 
LVEDD (LVEDD 2 ~ 2.09 3 genderfemale 1 0.56 3 LVEDD 1 
1 2.30 3 R403W; p 5 6.86e − 5). In the adult group, final 
LVESD was better explained by a model in which LVEDD 2 
replaced LVESD 1 (LVESD 2 ~ 0.86 3 PW 2 – 0.26 3 IVS 2 
1 0.77 3 LVEDD 2; p 5 3.55e − 10).
TABLE 2. ADDiTioNAL SYMPToMS AND fEATuRES iN R92WTNNT2 AND R403MYH7 MuTATioN CARRiERS AT  
fiNAL EvALuATioN
Pedigree Person
Mutation/
gene Gender
Age 2
(years) Symtoms Hypertension
Mitral 
regurgitation
Atrial 
fibrillation
NYHA
class
100 0_III_8 R92WTNNT2 M 48.0 0 0 Y 0 1
100 0_III_17 R92WTNNT2 M 38.0 D 0 0 0 2
100 0_II_18 R92WTNNT2 F 57.0 0 0 Y 0 1
100 0_III_20 R92WTNNT2 F 37.0 P 0 0 0 1
100 0_II_23 R92WTNNT2 F 51.0 P Y* Y AF 2
100 0_II_10 R92WTNNT2 F 67.0 0 0 0 0 1
100 0_III_9 R92WTNNT2 F 38.0 S 0 0 AF 1
100 0_III_12 R92WTNNT2 F 45.0 0 0 0 0 1
100 0_III_15 R92WTNNT2 F 42.0 0 0 0 0 1
100 0_III_5 R92WTNNT2 F 33.0 0 0 0 0 1
100 0_III_22 R92WTNNT2 M 19.0 S 0 0 0 1
109 9_III_1 R92WTNNT2 F 41.0 S, P, D 0 Y 0 3*
109 9_IV_2 R92WTNNT2 F 21.0 0 0 0 0 1
103 3_II_2 R92WTNNT2 M 43.0 S, A Y Y 0 1
137 37_II_3 R92WTNNT2 M 57.0 P 0 0 AF 1
137 37_III_2 R92WTNNT2 F 28.0 0 0 0 0 1
139 39_II_6 R92WTNNT2 M 40.0 0 0 Y 0 1
139 39_II_4 R92WTNNT2 F 44.0 S 0 0 0 1
139 39_II_8 R92WTNNT2 F 36.0 0 0 0 0 1
139 39_III_2 R92WTNNT2 M 16.0 S 0 0 0 1
139 39_III_4 R92WTNNT2 M 20.0 0 0 0 0 1
139 39_III_3 R92WTNNT2 F 17.0 0 0 0 0 1
106 6_III_13 R403WMYH7 M 72.0 0 0 0 0 1
106 6_III_15 R403WMYH7 M 65.0 0 0 Y 0 1
106 6_III_22 R403WMYH7 F 58.0 P Y Y 0 1
106 6_III_7 R403WMYH7 F 61.0 0 0 Y 0 1
106 6_IV_10 R403WMYH7 M 44.0 0 0 Y 0 1
106 6_IV_11 R403WMYH7 M 41.0 0 0 0 0 1
106 6_IV_12 R403WMYH7 F 39.0 0 0 0 0 1
106 6_IV_22 R403WMYH7 M 50.0 S Y 0 0 2
106 6_IV_23 R403WMYH7 F 48.0 0 Y Y 0 2
106 6_IV_24 R403WMYH7 F 47.0 0 0 Y 0 1
106 6_IV_25 R403WMYH7 F 44.0 0 0 Y 0 1
106 6_IV_31 R403WMYH7 M 36.0 0 0 0 0 1
106 6_IV_33 R403WMYH7 M 29.0 A 0 0 0 1
106 6_IV_6 R403WMYH7 M 50.0 0 0 0 0 1
106 6_IV_7 R403WMYH7 F 48.0 0 0 0 0 1
106 6_IV_8 R403WMYH7 M 46.0 0 0 0 0 1
106 6_V_5 R403WMYH7 M 29.0 0 0 0 0 1
106 6_V_6 R403WMYH7 M 26.0 0 0 0 0 1
106 6_V_7 R403WMYH7 M 24.0 0 0 Y 0 1
106 6_V_8 R403WMYH7 M 22.0 P, D, A 0 Y 0 2
106 6_IV_2 R403WMYH7 F 19.0 0 0 0 0 1
106 6_IV_30 R403WMYH7 M 27.0 0 0 0 0 1
106 6_V_11 R403WMYH7 F 19.0 0 0 0 0 1
106 6_V_14 R403WMYH7 M 20.0 0 0 0 0 1
106 6_V_17 R403WMYH7 M 22.0 0 0 0 0 1
106 6_V_4 R403WMYH7 M 18.0 0 0 0 0 1
Person 5 numbers refer to pedigree identification numbers; see Fig. 1 for pedigrees 103, 137 and 139, references 10 for pedigree 100 and 109 
and reference 11 for pedigree 106. *feature manifested during follow-up period.
M 5 male, F 5 female, Age 2 5 age at final evaluation, P 5 palpitations, D 5 dyspnoea, A 5 angina, Y 5 yes, 0 5 absent. 
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Discussion 
It is generally accepted that the initiation of hypertrophy in 
HCM occurs in puberty and progresses rapidly during adoles-
cence and early adult life, after which wall thickness stabilises 
from about middle age, unless the heart remodels due to wall 
thinning.2,3 This conventional view of the inverse correlation 
between hypertrophy and age has been thought to account for 
the paucity of older individuals manifesting severe hypertrophy.4 
The only reported exception to date has been the steady increase 
in hypertrophy with age seen in HCM caused by particular 
mutations in MYBPC.5 
Our study presents data that challenge the accepted view of 
the course of HCM, and indicate that increased hypertrophy, 
rather than wall thinning, probably continues during adult life 
more often than previously anticipated, even in individuals 
well past middle age. In our study, the majority of individuals 
showed an increase in IVS and/or PW, with more than 42% 
of R403WMYH7 and 46% of R92WTNNT2 carriers demonstrating 
a marked increase (≥ 5 mm) in IVS. More than a third of all 
mutation carriers developed clinically recognised hypertrophy 
after the age of 35 years. Therefore, both mutation groups 
would include individuals who might go on to develop HCM 
but who might, under conventional management in the absence 
of genetic information, remain undiagnosed, and therapeutic 
interventions would not be considered. 
This emphasises the insensitivity of standard echocardio-
graphy as a tool for identifying individuals at risk of developing 
HCM, regardless of their age. Whereas this may not be critical 
for carriers of mutations with mild phenotypic effects, such as 
the R403WMYH7 mutation, it may be particularly significant to 
unidentified carriers of the R92WTNNT2 mutation, where the peri-
od of hypertrophically silent HCM also coincided with the years 
in which most SCDs occurred, particularly in males (Fig. 2). 
Furthermore, in South African patients with the R92WTNNT2 
mutation, dilated cardiomyopathy is not an endpoint as has 
been suggested for Japanese patients with this mutation.9 These 
TABLE 3. MEAN CHANGE iN foLLoW-uP PARAMETERS BETWEEN BASELiNE AND fiNAL EvALuATioN iN R92WTNNT2  
AND R403WMYH7 MuTATioN CARRiERS
R92W (n 5 22) R403W (n 5 26)
Mean Median Min Max SD Mean Median Min Max SD p-values
Time (years) 10.32 11.00 4.00 14.00 3.86 11.73 11.00 11.00 14.00 1.08 0.591
Age 1 (years) 27.50 29.00 9.00 53.00 12.01 26.62 28.00 7.00 60.00 15.36 0.725
Age 2 (years) 38.09 39.00 16.00 67.00 13.80 38.62 40.00 18.00 72.00 15.63 0.780
IVS 1 (mm) 9.58 8.00 4.00 20.00 4.51 8.51 7.50 4.00 18.00 3.55 0.442
IVS 2 (mm) 14.23 15.50 6.00 22.00 5.09 12.93 12.60 7.20 23.00 3.95 0.282
% IVS change 63.06 57.14 −20.00 190.00 62.55 63.43 53.89 −14.29 208.00 48.53 0.869
PW 1 (mm) 7.62 7.00 4.00 13.00 2.31 7.38 7.00 3.00 13.00 2.15 0.892
PW 2 (mm) 8.82 8.80 6.00 13.20 2.08 8.99 8.80 6.00 12.00 1.62 0.619
% PW change 19.85 13.13 −17.50 80.00 25.13 30.06 23.33 −36.15 153.33 38.77 0.277
LAD 1 (mm) 32.26 33.00 20.00 45.00 6.02 29.58 29.00 20.00 43.00 5.35 0.117
LAD 2 (mm) 35.35 34.60 22.00 48.80 7.69 36.40 36.10 25.50 50.00 7.16 0.548
% LAD change 13.96 11.43 −21.43 51.48 20.20 23.75 23.13 −12.94 69.57 19.57 0.112
LVEDD 1 (mm) 43.55 43.50 34.00 52.00 5.06 45.96 46.50 34.00 57.00 6.59 0.168
LVEDD 2 (mm) 40.85 40.00 34.00 48.00 3.95 45.05 46.25 38.00 52.50 4.02 0.002
% LVEDD change −5.59 −7.15 −20.00 12.20 8.93 −0.58 −3.21 −25.44 34.29 13.05 0.203
LVESD 1 (mm) 25.32 26.00 16.00 34.00 4.87 25.65 25.50 16.00 34.00 4.68 0.959
LVESD 2 (mm) 23.60 24.40 16.10 33.20 3.93 27.94 28.00 22.00 36.00 3.38 0.000
% LVESD change −4.04 −4.77 −44.48 47.06 21.03 11.71 7.00 −23.03 71.43 21.27 0.009
EF 1 (%) 67.48 65.90 53.60 80.30 7.34 69.87 68.30 60.20 82.00 5.78 0.179
EF 2 (%) 67.51 68.05 51.50 84.30 8.05 62.69 63.00 53.90 71.10 4.30 0.009
% EF change 1.02 −2.02 −23.70 41.44 15.72 −9.22 −9.78 −34.27 8.75 8.77 0.017
Min 5 minimum, max 5 maximum, SD 5 standard deviation, 1 5 baseline measurement, 2 5 final measurement. Time 5 follow-up period, 
IVS 5 end-diastolic interventricular septal thickness, PW 5 end-diastolic posterior wall thickness, LAD 5 left atrial diameter, LVEDD 5 left 
ventricular end-diastolic diameter, LVESD 5 left ventricular end-systolic diameter, EF 5 ejection fraction, − 5 decrease in parameter between 
first and final evaluation.
TABLE 4. CoRRELATioNS BETWEEN PRoGRESSioN 
PARAMETERS AND MuTATioN, GENDER AND AGE iN 
THE CoMBiNED STuDY SAMPLE
Parameters
Mutation
r-value/p-value
Gender
r-value/p-value
Age 2
r-value/p-value
IVS 2 0.2711/
p 5 0.082
0.192/
 p5 0.223
0.6425/
p 5 0.000
% IVS change 0.0963/
p 5 0.544
−0.1299/
 p 5 0.412
−0.0538/
p 5 0.735
PW 2 0.0303/
p 5 0.849
0.2217/
p 5 0.158
0.5555/
p 5 0.000
% PW change −0.1479/
p 5 0.350
−0.0035/
p 5 0.982
−0.355/
p 5 0.021
LVEDD2 −0.4665/
p 5 0.002
−0.3094/
p 5 0.046
0.0368/
p 5 0.817
LAD2 0.0068/
p 5 0.966
−0.0191/
p 5 0.904
0.6059/
p 5 0.000
% LAD change 0.2457/
p 5 0.117
−0.001/
p 5 0.995
−0.0471/
p 5 0.767
% LVEDD 
change
−0.3185/
p 5 0.040
−0.0113/
p 5 0.943
−0.2559/
p 5 0.102
LVESD2 −0.5283/
p 5 0.000
−0.2549/
p 5 0.103
−0.1465/
p 5 0.355
% LVESD 
change
−0.4513/
p 5 0.003
0.0472/
p 5 0.766
−0.2887/
p 5 0.064
EF2 0.3891/
p 5 0.011
0.1034/
p 5 0.515
0.2839/
p 5 0.068
% EF change 0.4637/
p 5 0.002
−0.0197/
p 5 0.902
0.3005/
p 5 0.053
Age 2 5 age at final evaluation, IVS 5 end-diastolic interventricu-
lar septal thickness, PW 5 posterior wall thickness, LVEDD 5 left 
ventricular end-diastolic diameter, LVESD 5 left ventricular end-
systolic diameter, LAD 5 left atrial diameter, 2 5 final evaluation.
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findings emphasise that conclusions about genotype:phenotype 
correlations based on small numbers and cross-sectional data, 
particularly without consideration of covariates or confounders 
of the cardiac phenotype, may be misleading. 
Statistical analyses of the longitudinal follow-up data 
presented here reveal that, at least for these families, the causal 
mutation did not play a significant role in the eventual wall 
thickness attained, but that age and initial wall thickness were 
the greater determinants of increases in hypertrophy over time. 
However, multiple regression modelling shows that the particu-
lar mutation is the strongest determinant of LV remodelling, 
with the majority of R403WMYH7 carriers demonstrating LVESD 
increases and EF reduction. Although no R403WMYH7 carriers 
investigated in this study developed a full-blown DCM-like 
phenotype, females of this group demonstrated the strongest 
trend towards LV dilation. These latter observations were born 
out by multiple regression modelling which showed that, once 
age was adjusted for, female gender and the R403WMYH7 muta-
tion were the greatest contributors to LV dimensions, either 
directly to LVEDD, or indirectly to LVESD (via LVEDD). Taken 
together, these data also suggest that even individuals with a 
‘mild’ HCM mutation or minimal hypertrophy at diagnosis may 
require clinical follow-up over the longer term. 
Conclusions 
Our study shows that the absence of clinically recognised hyper-
trophy, particularly in those with a family history of unexplained 
SCD, is not sufficient grounds to assume absence of HCM and 
its consequences, as hypertrophy may develop at a later age, or 
may be preceded by SCD. Individuals with or without hypertro-
phy, belonging to an HCM family with a history of SCD should 
be assessed for additional risk factors and managed accord-
ingly.16 In South Africa, the R92WTNNT2 and R403WMYH7 mutations 
are founder mutations,17 and therefore more frequent causes 
of HCM, for which genetic tests are available. A negative test 
reduces the risk of HCM to that of the man on the street, while 
a positive test for either mutation can assist in identifying those 
individuals in need of regular follow-up, even prior to develop-
ment of hypertrophy. 
The study limitations include modest numbers of patients 
investigated and the inevitable dissimilarity in baseline and final 
investigations, introduced by changes in echocardiographic 
technology and technologists over the study period. However, 
this study illustrates that the pursuit and subsequent statistical 
analysis of longitudinal follow-up data may facilitate a greater 
understanding of the interrelated factors that precipitate the 
eventual HCM phenotype. 
Our data suggest that an interplay between unidentified 
modifying factors, which may include gender-related factors 
associated with other cardiovascular diseases (reviewed in refer-
ence 18), and the causal mutation, determines eventual cardiac 
function as well as the risk for SCD. Investigations of families 
such as those with R92WTNNT2, who share the same HCM-causing 
mutation and therefore reduced variability ascribed to variations 
in the primary disease-causing defect, may allow dissection of 
such modifying factors in future. Until the interactions between 
disease-causing mutation, and environmental and genetic modi-
fying factors are more fully delineated, there remains a need to 
continue echocardiography and other clinical investigations well 
past middle age to identify at-risk individuals and to monitor 
even those with initially mild hypertrophy, in order to facilitate 
appropriate management and treatment. 
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